Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Menopausal Status Modifies Breast Cancer Risk Associated with ESR1 PvuII and XbaI Polymorphisms in Asian Women: a HuGE Review and Meta-analysis

  • Li, Li-Wen (School of Public Health, Shanghai Jiaotong University) ;
  • Xu, Lei (Pudong District Centre for Disease Control and Prevention)
  • Published : 2012.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Published data on the association between single nucleotide polymorphisms (SNPs) in the ESR1 gene and breast cancer susceptibility are inconclusive or controversial. The aim of this Human Genome Epidemiology (HuGE) review and meta-analysis was to derive a more precise estimation of this relationship. Methods: A literature search of Pubmed, Embase, Web of science and CBM databases was conducted from inception through September 1th, 2012. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of association. Results: A total of five studies including 1,678 breast cancer cases and 1,678 general population controls in Asian populations were involved in this meta-analysis. When all the eligible studies were pooled into the meta-analysis, the higher transcriptional activity variant allele T of ESR1 PvuII (C>T) (rs2234693) in pre-menopausal breast cancer women showed a significant relation to increased risk (OR = 1.13, 95%CI: 1.01-1.28, P = 0.040) in contrast to their post-menopausal counterparts which showed non-significant increased risk (OR = 1.01, 95%CI: 0.87-1.18, P = 0.858). Nevertheless, no significant association between ESR1 XbaI (A>G) (rs9340799) polymorphism and the risk of breast cancer was observed in pre-menopausal and post-menopausal individuals. Conclusion: Based on a homogeneous Asian population, results from the current meta-analysis indicates that the ESR1 PvuII (C>T) polymorphism places pre-menopausal breast cancer women at risk for breast cancer, while ESR1 XbaI (A>G) polymorphism is not likely to predict the risk of breast cancer.

Keywords

References

  1. Baade PD, Youlden DR, Chambers SK (2011). When do I know I am cured? Using conditional estimates to provide better information about cancer survival prospects. Med J Aust, 194, 73-7.
  2. Butt Z, Haider SF, Arif S, et al (2012). Breast cancer risk factors: a comparison between pre-menopausal and post-menopausal women. J Pak Med Assoc, 62, 120-4.
  3. Cai Q, Shu XO, Jin F, et al (2003). Genetic polymorphisms in the estrogen receptor alpha gene and risk of breast cancer: results from the Shanghai Breast Cancer Study. Cancer Epidemiol Biomarkers Prev, 12, 853-9.
  4. Campeau PM, Foulkes WD, Tischkowitz MD (2008). Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet, 124, 31-42. https://doi.org/10.1007/s00439-008-0529-1
  5. da Costa BR, Cevallos M, Altman DG, et al (2011). Uses and misuses of the STROBE statement: bibliographic study. BMJ Open, 1, e000048. https://doi.org/10.1136/bmjopen-2010-000048
  6. Deng LL: A study on the relationship between Xba I and PvuII polymorphism of ESR1 gene and breast cancer (2011).
  7. Ding SL, Yu JC, Chen ST, et al (2010). Diverse associations between ESR1 polymorphism and breast cancer development and progression. Clin Cancer Res, 16, 3473-84. https://doi.org/10.1158/1078-0432.CCR-09-3092
  8. Einarsdottir K, Darabi H, Li Y, et al (2008). ESR1 and EGF genetic variation in relation to breast cancer risk and survival. Breast Cancer Res, 10, R15. https://doi.org/10.1186/bcr1861
  9. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. https://doi.org/10.1002/ijc.25516
  10. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58. https://doi.org/10.1002/sim.1186
  11. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  12. Jeon S, Choi JY, Lee KM, et al (2010). Combined genetic effect of CDK7 and ESR1 polymorphisms on breast cancer. Breast Cancer Res Treat, 121, 737-42. https://doi.org/10.1007/s10549-009-0640-6
  13. Key T, Appleby P, Barnes I, et al (2002). Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst, 94, 606-16. https://doi.org/10.1093/jnci/94.8.606
  14. Laudanski P, Koda M, Kozlowski L, et al (2004). Expression of glucose transporter GLUT-1 and estrogen receptors ER-alpha and ER-beta in human breast cancer. Neoplasma, 51, 164-8.
  15. Li N, Dong J, Hu Z, et al (2010). Potentially functional polymorphisms in ESR1 and breast cancer risk: a meta-analysis. Breast Cancer Res Treat, 121, 177-84. https://doi.org/10.1007/s10549-009-0532-9
  16. Li Y, Ambrosone CB, McCullough MJ, et al (2009). Oxidative stress-related genotypes, fruit and vegetable consumption and breast cancer risk. Carcinogenesis, 30, 777-84. https://doi.org/10.1093/carcin/bgp053
  17. Lu X, Li B, Wei JM, et al (2005). The XbaⅠsand PvuⅡgene polymorphiams of the estrogen receptor αgene in Chinese women with breast cancer. Chin J Surg, 43, 21-4.
  18. McCormack VA, Boffetta P (2011). Today's lifestyles, tomorrow's cancers: trends in lifestyle risk factors for cancer in low- and middle-income countries. Ann Oncol, 22, 2349-57. https://doi.org/10.1093/annonc/mdq763
  19. Pabalan N, Jarjanazi H, Sung L, et al (2012). Menopausal status modifies breast cancer risk associated with the myeloperoxidase (MPO) G463A polymorphism in Caucasian women: a meta-analysis. PLoS One, 7, e32389. https://doi.org/10.1371/journal.pone.0032389
  20. Parker MG, Cowley SM, Heery D, et al (1997). Function of estrogen receptors in breast cancer. Breast Cancer, 4, 204-8. https://doi.org/10.1007/BF02966506
  21. Peters JL, Sutton AJ, Jones DR, et al (2006). Comparison of two methods to detect publication bias in meta-analysis. JAMA, 295, 676-80. https://doi.org/10.1001/jama.295.6.676
  22. Sakoda LC, Blackston CR, Doherty JA, et al (2011). Selected estrogen receptor 1 and androgen receptor gene polymorphisms in relation to risk of breast cancer and fibrocystic breast conditions among Chinese women. Cancer Epidemiol, 35, 48-55. https://doi.org/10.1016/j.canep.2010.08.005
  23. Shen Y, Li DK, Wu J, et al (2006). Joint effects of the CYP1A1 MspI, ERalpha PvuII, and ERalpha XbaI polymorphisms on the risk of breast cancer: results from a population-based case-control study in Shanghai, China. Cancer Epidemiol Biomarkers Prev, 15, 342-7. https://doi.org/10.1158/1055-9965.EPI-05-0485
  24. Shin A, Kang D, Nishio H, et al (2003). Estrogen receptor alpha gene polymorphisms and breast cancer risk. Breast Cancer Res Treat, 80, 127-31. https://doi.org/10.1023/A:1024439202528
  25. Sobti RC, Askari M, Nikbakht M, et al (2012). Genetic variants of EGFR (142285G>A) and ESR1 (2014G>A) gene polymorphisms and risk of breast cancer. Mol Cell Biochem, 369, 217-25. https://doi.org/10.1007/s11010-012-1384-x
  26. Song CG, Hu Z, Yuan WT, et al (2006). Er-${\alpha}$ gene polymorphism and the risk of non-BRCA1/2 hereditary breast cancer. Chin J Gen Surg, 21, 637-40.
  27. Stuckey A (2011). Breast cancer: epidemiology and risk factors. Clin Obstet Gynecol, 54, 96-102. https://doi.org/10.1097/GRF.0b013e3182080056
  28. Surekha D, Vishnupriya S, Rao DN, et al (2007). PvuII polymorphism of estrogen receptor-alpha gene in breast cancer. Indian J Hum Genet, 13, 97-101. https://doi.org/10.4103/0971-6866.38983
  29. Tsezou A, Tzetis M, Gennatas C, et al (2008). Association of repeat polymorphisms in the estrogen receptors alpha, beta (ESR1, ESR2) and androgen receptor (AR) genes with the occurrence of breast cancer. Breast, 17, 159-66. https://doi.org/10.1016/j.breast.2007.08.007
  30. Weiderpass E, Persson I, Melhus H, et al (2000). Estrogen receptor alpha gene polymorphisms and endometrial cancer risk. Carcinogenesis, 21, 623-7. https://doi.org/10.1093/carcin/21.4.623
  31. Zhang FC, Xu YC, Lin YM (2004). Association between ESR1 and breast cancer. Conference article.
  32. Zhang L, Liu JL, Zhang YJ, et al (2011). Association between HLA-B*27 polymorphisms and ankylosing spondylitis in Han populations: a meta-analysis. Clin Exp Rheumatol, 29, 285-92.
  33. Zhang W, Yu YY (2007). Polymorphisms of short tandem repeat of genes and breast cancer susceptibility. Eur J Surg Oncol, 33, 529-34. https://doi.org/10.1016/j.ejso.2006.11.027
  34. Zintzaras E, Ioannidis JP (2005). Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol, 28, 123-37. https://doi.org/10.1002/gepi.20048

Cited by

  1. ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer vol.154, pp.3, 2015, https://doi.org/10.1007/s10549-015-3634-6
  2. A Meta-Analysis of the Association between ESR1 Genetic Variants and the Risk of Breast Cancer vol.11, pp.4, 2016, https://doi.org/10.1371/journal.pone.0153314
  3. Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial vol.18, pp.1, 2016, https://doi.org/10.1186/s13058-016-0771-8
  4. Peroxisome proliferator-activated receptor γ2 Pro12Ala (rs1801282) polymorphism and breast cancer susceptibility: A meta-analysis vol.8, pp.6, 2013, https://doi.org/10.3892/mmr.2013.1735
  5. Comment on “Estrogen receptor alpha (ERS1) SNPs c454-397T>C (PvuII) and c454-351A>G (XbaI) are risk biomarkers for breast cancer development” pp.1573-4978, 2018, https://doi.org/10.1007/s11033-018-4452-9
  6. Association between ERα gene Pvu II polymorphism and breast cancer susceptibility vol.97, pp.17, 2018, https://doi.org/10.1097/MD.0000000000010317